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Inhibition of human erythrocyte acetylcholinesterase (AChE; EC
3.1.1.7) and serum butyrylcholinesterase (BChE; EC 3.1.1.8) by etho-
propazine, 10-(2-diethylaminopropyl)phenothiazine hydrochloride, was
measured with acetylthiocholine (ATCh) as substrate. Dissociation
constants for the enzyme-inhibitor complexes were calculated from
the effect of ATCh concentration on the apparent dissociation con-
stants by applying non-linear regression to fit the model to experi-
mental data. Inhibition of AChE revealed a competitive inhibition
for two binding sites (Ka = 161 and Ki = 393 mol dm–3), inhibition
of the atypical BChE was non-competitive (Ki = 7.5 mol dm–3) while
that of the usual BChE was competitive (K(I) = 0.16 mol dm–3).
At the ethopropazine concentration of 20 mol dm–3 and the acetyl-
thiocholine concentration of 1.0 mmol dm–3 (conditions used for dif-
ferentiation between AChE and BChE activities), the erythrocyte
AChE was 8% inhibited and the BChE phenotypes UU, UA, FF/FS,
AF, AJ/AK and AA/AS between 98% and 74%.
Key words: acetylcholinesterase, butyrylcholinesterase, ethopropa-
zine, selective inhibition, inhibition mechanism, enzyme-inhibitor
and enzyme-substrate dissociation constants.
INTRODUCTION
Ethopropazine is one of the phenothiazine derivatives that are potent in-
hibitors of butyrylcholinesterase (BChE, EC 3.1.1.8), but poor inhibitors of
acetylcholinesterase (AChE, EC 3.1.1.7). As the most potent and selective
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inhibitor among phenothiazine derivatives, ethopropazine is used to inhibit
selectively BChE in samples where both BChE and AChE are present.1–4
Ethopropazine has a quaternary nitrogen in the structure (Figure 1), and
one may expect that it inhibits the usual human serum BChE to a higher
degree than the atypical enzyme or its heterozygotes. We confirmed this as-
sumption in a preliminary study.5
This paper deals with the inhibition of human serum BChE variants and
of human erythrocyte AChE by racemic ethopropazine. The selectivity of etho-
propazine for different human BChE phenotypes and for human erythrocyte
AChE was determined under the experimental conditions used for assess-
ment of AChE and BChE activities in human blood. To get more information
on the inhibition mechanism of the two enzymes, the dissociation constants
of the enzyme-inhibitor complexes were determined from the effect of the
substrate upon the degree of inhibition.
EXPERIMENTAL
Enzyme Source
The source of AChE was human erythrocytes washed with buffer to remove the
plasma. Sera were taken from individuals whose BChE phenotypes had previously
been determined by measuring the activity with propionylthiocholine as substrate
and the inhibition with benzoylcholine as substrate using dibucain, sodium fluoride
and Ro 02-0683 as differentiating inhibitors.6–8 The phenotypes were homozygotes or
heterozygotes of the usual (U), atypical (A), fluoride-resistant (F), Kalow (K), J, or si-
lent (S) BChE variants.
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Figure 1. Chemical structure of ethopropazine.
Reagents
Ethopropazine (Sigma, St. Louis, USA) was a gift from Professor P. Eyer. Acetyl-
thiocholine iodide (ATCh) was from Sigma St. Louis, USA.
Activity Measurement
Activity of the enzymes was measured with ATCh in 0.1 mol dm–3 phosphate buffer,
pH = 7.4 at 37 C with the thiol reagent DTNB.9 In the final reaction mixture, erythro-
cytes and serum were diluted 600 and 150 times, respectively. Activities measured
at ATCh concentrations of 0.5 mmol dm–3 or higher were corrected for spontaneous
substrate hydrolysis. More details of the procedure were described earlier.10,11
Enzyme Inhibition
The selectivity of ethopropazine for AChE and BChE was tested with ethopro-
pazine concentration of 20 mol dm–3 and ATCh concentration of 1.0 mmol dm–3. To
study the competition between ethopropazine and the substrate, the activity of AChE
and BChE was measured in the absence and presence of ethopropazine with ATCh
concentrations ranging between 0.1 and 10 mmol dm–3. From experimental data thus
obtained, enzyme-inhibitor and enzyme-substrate dissociation constants were calcu-
lated from the equations, based on the assumption that the enzyme has a peripheral
(allosteric) site where substrates or inhibitors can bind.13
If both, substrate and inhibitor, bind to both sites on the enzyme (catalytic and
peripheral), the equation which relates substrate and inhibitor concentrations to en-
zyme activities is:13
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where 0 and  are the enzyme activities at a given substrate concentration (s) in the
absence and presence of the inhibitor (concentration: i). In this equation, the appar-
ent dissociation constant Kapp is a function of both inhibitor and substrate concentra-
tions. The Ks, Kss, Ka and Ki are dissociation constants of enzyme-substrate and en-
zyme-inhibitor complexes at the catalytic and peripheral sites, respectively.
If the inhibitor binds only to the catalytic site or only to the peripheral site, and
the substrate binds to both sites, the effect of substrate concentration upon Kapp is



















K(I) is either the enzyme-inhibitor dissociation constant at the catalytic site (Ka)
or the dissociation constant at the peripheral site (Ki), and K(S) is the enzyme-sub-
strate dissociation constant at the respective sites (Ks or Kss). It follows from Eq. (2)
that Kapp is only a function of the substrate concentration.
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Finally, if Kapp does not change with the change of substrate concentration, a










The enzyme-inhibitor and enzyme-substrate dissociation constants were calcu-
lated from the above equations by the MacCurvefit Programme applying the Quasi-
Newton minimisation algorithm.
RESULTS
Selectivity of Ethopropazine for Acetylcholinesterase
and Butyrylcholinesterase
Absorption of cholinesterase inhibitors is commonly assessed by measur-
ing the decrease of AChE and/or BChE activities in human blood. If activi-
ties are measured in whole blood, i.e. without separating the erythrocytes
from plasma, one should apply either a specific substrate or a specific inhibi-
tor of AChE or BChE in order to assess the activity of only one enzyme. Etho-
propazine has been suggested as a specific BChE inhibitor, which at the con-
centration of 20 mol dm–3 fully inhibits the BChE activity without inhibiting
AChE, and procedures have been worked out for the differentiation of the
two enzymes in whole blood.2,3
In this paper we have tested ethopropazine as an inhibitor of BChE va-
riants and of erythrocyte AChE. Inhibition was measured with the ethopro-
pazine concentration of 20 mol dm–3 using ATCh (1.0 mmol dm–3) as sub-
strate (Table I).
The mean activities (mol min–1 mL–1) of the studied BChE variants
ranged from 2.86 for the usual BChE (UU) to 0.41 for the atypical enzyme
(AA/AS). All six variants were inhibited by the ethopropazine concentration
of 20 mol dm–3. The degree of inhibition decreased in almost the same or-
der as the rates of ATCh hydrolysis: the UU BChE, which is most active,
was 98% inhibited while the AA/AS BChE was only 74% inhibited. Under
the same experimental conditions, ethopropazine (20 mol dm–3) inhibited
8% of erythrocyte AChE, which is consistent with 5% inhibition reported by
Worek et al.3
Consequently, ethopropazine is a very potent inhibitor of BChE. How-
ever, when ethopropazine is applied as inhibitor of BChE in order to mea-
sure the AChE activity in human whole blood, AChE will also be slightly
inhibited. On the other hand, when blood contains a homozygous or hetero-
zygous A variant of BChE, inhibition of the serum BChE by ethopropazine
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(20 mol dm–3) will be less than 98%. Both of these facts should be taken
into account when validating procedures for the AChE activity measure-
ments in whole blood, based on BChE inhibition by ethopropazine.12
Reversible Binding of Ethopropazine to Acetylcholinesterase
and Butyrylcholinesterase
To determine the dissociation constants of the ethopropazine complexes
with AChE or BChE, inhibition was measured with a broad range of etho-
propazine concentrations in order to reach a degree of inhibition between 20
to 80%. Experimental data were interpreted according to the models described
by Eqs. (1–3).
The apparent dissociation constants Kapp for inhibition of AChE and BChE
as a function of the ATCh concentration (Hunter-Downs plots) are shown in
Figure 2.
The Hunter-Downs plot for the inhibition of erythrocyte AChE displayed
a curve. Applying Eq. (1), a theoretical curve and the best fitting dissociation
constants Ks, Kss, Ka and Ki were calculated (Table II). The curve fitting was
done for the ethopropazine concentration of 200 mol dm–3 because that con-
centration was used in the experiments. The theoretical curves calculated
for ethopropazine concentrations of 200 and 400 mol dm–3 fell within one
standard deviation of the experimental points. The calculated Ks and Kss
values (Table II) are in good agreement with the Km and Kss constants we
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TABLE I
Activities of AChE and BChE, and inhibition of cholinesterases by ethopropazine











Erythrocyte AChE 6 4.66  1.08 08  4
Serum BChE phenotype
UU 4 2.86  0.57 98  2
UA 4 1.92  0.33 94  1
FF/FS 5 0.66  0.11 92  1
AF 3 0.85  0.26 87  1
AJ/AK 6 0.51  0.14 85  3
AA/AS 5 0.41  0.04 74  4
a Mean  SD. Mean values were calculated from measurements done on erythrocytes or sera
from N individuals.
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Figure 2. Inhibition of erythrocyte acetylcholinesterase (AChE) and serum butyryl-
cholinesterase (BChE) variants (UU and AA/AS) by ethopropazine, measured with
acetylthiocholine (ATCh) as substrate. Kapp is defined by Eqs. (1), (2) or (3). Each
point is the mean value of 4–7 experiments. The lines were calculated as described
under Experimental.
calculated from the data for erythrocyte AChE and ATCh in the absence of
ethopropazine (0.1 and 5.7 mmol dm–3, respectively).
The Hunter-Downs plot for the usual BChE displayed competitive inhi-
bition and Eq. (2) was therefore applied (Table II). However, the Kapp values
measured at ATCh concentrations of 0.10 and 0.25 mmol dm–3 were almost
the same, 0.19 and 0.20 mol dm–3 respectively, indicating a non-competi-
tive component of inhibition at low substrate concentrations. As the K(I) con-
stant derived from Eq. (2) (Table II) was not significantly different from the
above two Kapp values, we find it justified to attribute only one enzyme-in-
hibitor dissociation constant to the inhibition of the usual BChE by etho-
propazine. The value of the K(S) constant derived from Eq. (2) (Table II) was
between two enzyme-substrate dissociation constants calculated in the ab-
sence of ethopropazine either from data in this paper (K1 = 0.04 mmol dm
–3
and K2 = 1.2 mmol dm
–3) or in a previous study (K1 = 0.04 mmol dm
–3 and
K2 = 1.8 mmol dm
–3).10 These enzyme-substrate dissociation constants were
calculated by applying an equation which assumes two binding sites for the
substrate on the enzyme.14
Inhibition of the atypical BChE was non-competitive over the total
ATCh concentration range studied. This follows from Figure 2 and also from
the analysis of Kapp values at ATCh concentrations of 0.10 and 10 mmol dm
–3,
which were not significantly different (t = 1.99, at the 0.094 significance le-
vel). The non-competitive inhibition constant Ki was therefore calculated as
the mean of all the measured Kapp values according to Eq. (3) (Table II). Ac-
cording to the model underlying Eqs. (1–3), the non-competitive feature of
inhibition points to the involvement of the peripheral site in the inhibition
mechanism.
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TABLE II
Dissociation constants for enzyme-inhibitor and enzyme-substrate complexes


















0.1–10 0.25–2 K(I) = 0.16  0.03 K(S) = 0.69  0.14
AA phenotype
BChE
0.1–10 2–10 Ki = 7.5  1.4 –
DISCUSSION AND CONCLUSION
Differentiation between AChE and BChE activities is routinely done with
ethopropazine (20 mol dm–3) as a potent BChE inhibitor, and the activities
are measured with ATCh (1 mmol dm–3) as substrate. It follows from the
evaluated enzyme-inhibitor dissociation constants given in Table II that under
these conditions the erythrocyte AChE and the usual BChE variant would
be inhibited 6% and 98%, respectively. The atypical BChE variant would be
inhibited 73% at any ATCh concentration between 0.1 and 10 mmol dm–3.
The measured percents of inhibition given in Table I agree well with these
values, calculated from the enzyme-inhibitor dissociation constants. This in
turn means that the equations applied to the calculation of the dissociation
constants are valid over a broad range of ethopropazine concentrations, in-
cluding the concentration of 20 mol dm–3 which was not used in the experi-
ments wherefrom the respective dissociation constants were calculated (Ta-
ble II).
The competition between ethopropazine and acetylthiocholine clearly shows
a difference between AChE and BChE. AChE displays two binding sites, and
ATCh competes with ethopropazine at both sites. The atypical BChE displays
a non-competitive inhibition, which indicates a peripheral binding site for
ethopropazine. The usual BChE reveals primarily a competitive inhibition,
which however has a non-competitive component at low substrate concen-
trations. Attribution of only one enzyme-inhibitor dissociation constant might
therefore be an oversimplification of the inhibition mechanism.
The affinity of ethopropazine for the usual BChE is three-orders of mag-
nitude higher than for the AChE. Similar differences between the inhibition
of AChE and BChE were found for enzymes from other sources. The speci-
ficity of ethopropazine in interaction with cholinesterases was demonstrated
through molecular modelling and confirmed by site specific mutagenesis. The
selectivity was related to the presence of a bulky aromatic residue, tyrosine
or phenylalanine, in AChE, in place of an alanine found at the correspond-
ing position in BChE. For this reason, the binding site is more spacious in
BChE and is capable of admitting the bulky ethopropazine.4,15,16
Positively charged compounds are better inhibitors of the usual BChE
variant than of the atypical variant,6,17 and this was also confirmed for etho-
propazine (Tables I and II) which has a quaternary nitrogen in the molecule
(Figure 1). The affinity of ethopropazine for the usual phenotype was about
50-fold higher than for the atypical phenotype, which results from the one-
point mutation in the atypical enzyme (Asp 70 Gly) as compared to the
usual enzyme. The AJ/AK sera were inhibited less than the usual enzyme
due to the presence of the atypical variant in heterozygotes; mutations on J
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and K variants are outside the active site and they are not critical for the
binding of substrates or inhibitors.18,19
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SA@ETAK
Inhibicija acetilkolinesteraze i butirilkolinesteraze iz ljudske krvi
etopropazinom
Vera Simeon-Rudolf, Goran [inko, Anita [tuglin i Elsa Reiner
Inhibicija ljudske eritrocitne acetilkolinesteraze (AChE, EC 3.1.1.7) i serumske
butirilkolinesteraze (BChE, EC 3.1.1.8) etopropazinom, 10-(2-dietilaminopropil)feno-
tiazin-hidrokloridom, mjerena je pri raznim koncentracijama supstrata acetiltioko-
lina. Disocijacijske konstante kompleksa enzim-inhibitor izra~unane su iz utjecaja
supstrata na prividne disocijacijske konstante nelinearnom regresijom, prema mo-
delima definiranim teorijskim jednad`bama. Inhibicija AChE bila je kompetitivna u
cijelom podru~ju koncentracije supstrata i uo~ena su dva vezna mjesta (Ka = 161 i
Ki = 393 mol dm
–3). Inhibicija atipi~ne BChE bila je nekompetitivna (Ki = 7,5 mol
dm–3), a obi~ne BChE kompetitivna (K(I) = 0,16 mol dm
–3). Pri koncentracijama eto-
propazina od 20 mol dm–3 i acetiltiokolina od 1,0 mmol dm–3 (uvjeti kori{teni za
razlikovanje aktivnosti BChE i AChE) eritrocitna AChE bila je inhibirana 8%, a BChE
(fenotipovi UU, UA, FF/FS, AF, AJ/AK i AA/AS) izme|u 98% i 74%.
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